3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Sarcoma
2
Recurrence
2
Melanoma
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Interventions
Cyclophosphamide
25
Temozolomide
22
Vincristine
18
Irinotecan
18
Doxorubicin
13
Topotecan
10
Melphalan
10
Etoposide
10
Ifosfamide
8
Busulfan
8
cabozantinib
7
Magnetic Resonance Spectroscopy
7
Granulocyte Colony-Stimulating Factor
7
Filgrastim
6
regorafenib
5
fludarabine
5
X-Rays
5
Specimen Handling
5
Sirolimus
5
Radiotherapy
5
Gemcitabine
5
Drug Therapy
5
pegfilgrastim
4
palbociclib
4
liposomal doxorubicin
4
irinotecan sucrosofate
4
ganitumab
4
fludarabine phosphate
4
Trabectedin
4
Phantoms, Imaging
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Ewing
×
bempegaldesleukin
×
Sarcoma
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts